Affordable Combinations in T2DM care: Scope of Glipizide, Metformin and Glimepiride, Metformin, Pioglitazone
Dual therapy of Glipizide + Metformin and the triple drug combination of Glimepiride + Metformin + Pioglitazone emerges as effective, safe, and affordable options for achieving glycemic control in the management of type 2 diabetes mellitus (T2DM), a latest review article concluded.
This article authored by Indian doctors has been published in the May 2024 edition of Cureus, a wing of the Springer Nature Journal.
The review emphasized that efficient T2DM management relies on cost-effective interventions to improve patient adherence.
Here are key highlights from this paper:
1) The combination of Glipizide and Metformin is effective in achieving optimal glycemic control, among T2DM patients with aberrant glycemic variables over three months despite metformin monotherapy
2) A triple-dose combination of Glimepiride, Metformin, and Pioglitazone has shown significant effectiveness in glycemic control, with an HbA1c level decrease by 1.3%. The combination has been proven in the Indian population to provide good glycemic goals and lipid levels.
Adapted from
1) Shaikh S, Vaidya V, Gupta A, et al. (May 07, 2024) A Review on Affordable Combinations in Type 2 Diabetes Care: Exploring the Cost-Effective Potential of Glipizide + Metformin and Glimepiride + Metformin + Pioglitazone. Cureus 16(5): e59850. doi:10.7759/cureus.59850
